« Back
Home /
Zosuquidar (trihydrochloride)

Zosuquidar (trihydrochloride)

Item no.	HY-50671-5mg
Manufacturer	MedChem Express
CASRN	167465-36-3
Amount	5 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	99.79
Citations	[1]A H Dantzig, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996 Sep 15;56(18):4171-9.\|[2]Ruoping Tang, et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer. 2008 Feb 13;8:51.\|[3]Larry D Cripe, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010 Nov 18;116(20):4077-85. Biochem Biophys Res Commun. 2021 May.\|Biomed Res Int. 2014;2014:850493. \|J Chromatogr B Analyt Technol Biomed Life Sci. 2018 May 31;1092:72-81. \|J Pharm Biomed Anal. 2012 Jul;66:232-9.\|Viruses. 2020 Aug 17;12(8):901.\|Antiviral Res. 2021 Jun 28;105124.\|Biomed Pharmacother. 2020 Sep;129:110506.\|Biomed Res Int. 2020 Nov 29;2020:8878158.\|bioRxiv. 2024 November 03.\|Blood Adv. 2020 Oct 27;4(20):5062-5077.\|Cancer Cell. 2017 Apr 10;31(4):501-515.e8. \|Crit Rev Anal Chem. 2021 Mar 10;1-15.\|Drug Metab Dispos. 2017 May;45(5):449-456.\|Exp Ther Med. 2020 Dec 7.\|Pharmaceutics. 2021, 13(4), 559.
Smiles	FC1([C@H]2[C@@H]1C3=C([C@@H](C4=CC=CC=C42)N5CCN(CC5)C[C@H](COC6=C7C=CC=NC7=CC=C6)O)C=CC=C3)F.Cl.Cl.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	RS 33295-198 trihydrochloride,LY-335979 trihydrochloride
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	P-glycoprotein
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	636.99
Product Description	Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research[1][2][3].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 1 mg/mL (ultrasonic)\|H2O: 5 mg/mL (ultrasonic)
Manufacturer - Pathway	Membrane Transporter/Ion Channel
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-50671-5mg-safety-datasheet.pdf